Skip to main content
OpenTrials
Completed

NCT Number: NCT02653638

Blood Brain Flow and Exercise

Cerebral vasodilator responses to CO2 will be measured in young healthy adults, healthy sedentary older adults, and healthy exercise trained older adults. This variable will be examined before and after administering the cyclooxygenase inhibitor indomethacin, which has been shown to blunt cerebral vasodilator responses. In addition, the investigators will examine these counter-regulatory hemodynamic mechanisms to hypoperfusion caused by indomethacin.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Gymnasium-Natatorium

Madison, Wisconsin, 53716, United States

About this study

Normal aging reduces cerebral blood flow and cognitive function. Aging also appears to alter functional connectivity within the brain, which is associated with cognitive functioning. Observational studies suggest that regular physical activity is associated with higher cerebral blood flow and improved cognitive function. However, the mechanistic links among regular physical activity and cerebral blood flow with advancing age are unknown. In this context, it is unclear if aging or exercise training status alters the neurovascular coupling of blood flow in the brain. Thus, the overall goal of this study is to examine the age-related changes in cerebral vasodilatory capacity, an important homeostatic mechanism and marker for effective regulation of cerebral perfusion, in order to determine how it is mechanistically linked to cognition. Additionally, the investigators will explore the potential beneficial effect of physical activity on the relationships between cerebral vasodilation and cognition in humans.

The research aims are:

  • To determine if cerebral vasodilator responses are affected by age and exercise training status in healthy adults.
  • To compare the effect of cyclooxygenase inhibition on cerebral vasodilator responses in healthy adults.
  • To determine the neurovascular counter-regulatory response to cyclooxygenase inhibition in healthy adults.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Young subjects between 18-35 years old
  • Older subjects between 55-75 years old
  • Nonsmokers
  • Physically active (exercise more than 3 times per week for at least 30 minutes)
  • Sedentary (no formal exercise over 1 hour per week).

Exclusion criteria

  • Outside of the specified age range
  • Present with history or evidence of hepatic, renal, or hematological disease; peripheral vascular disease; stroke/neurovascular disease; diabetes; hypertension
  • Take medications that indicate hepatic, renal, hematological disease; cardiovascular disease, including hypertension; stroke/neurovascular disease; and diabetes
  • Body mass index >34 kg/m2
  • Take physician-prescribed medications that may interact with indomethacin: 1) cardiovascular drugs (e.g. angiotensin-converting-enzyme inhibitor (ACE inhibitors), angiotensin II receptor blockers (ARB's), Diuretics); 2) drugs that would increase bleeding risk (e.g. warfarin, heparin, clopidogrel, rivaroxaban, other NSAIDs); or 3) drugs associated with increased renal toxicity (e.g. cyclosporin, tacrolimus)
  • Vulnerable populations (i.e. pregnant women, prisoners, individuals lacking capacity to consent, etc.)

Treatment and study plan

Control

Other
  • Transcranial Doppler
  • Blood Pressure
  • Heart Rate
  • Oxygen Saturation

Indomethacin

Drug
  • Transcranial Doppler
  • Blood Pressure
  • Heart Rate
  • Oxygen Saturation

Primary outcomes

  1. Cerebral Vasodilator Responses

    Time frame: Measurement at baseline

    Utilize a Transcranial Doppler to measure blood flow velocity in response to inhaled carbon dioxide.

Secondary outcomes

  1. Cerebral Vasodilator Responses

    Time frame: Measurement beginning 60 minutes post drug and measured through 180 minutes

    Utilize a Transcranial Doppler to measure blood flow velocity in response to inhaled carbon dioxide.

  2. Blood Pressure

    Time frame: Measurement at baseline and beginning 60 minutes post drug and measured through 180 minutes

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institutes of Health (NIH)

Registry information

Official study title

Cerebral Vasodilator Responses in Sedentary and Exercise Trained Humans

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jan 12, 2016
Registry last updated
Dec 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.